Gilead Sciences, Inc. (Jobs) Can't Seem To Please

What goes up must come down and Gilead Sciences knows this better than most. Shares of the biotechnology company slipped on Friday despite a 54% jump in profit after rising prior to the release of the company’s second-quarter earnings report. The reason? Lower-than-expected sales of HIV drug Atripla.

Back to news